Bioequivalence study of rimegepant Zydis® ODT formulation
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- 05 Jun 2018 According to a Biohaven Pharmaceutical Holding Company media release, expanded data will be presented at the American Headache Society (AHS) 60th Annual Scientific Meeting 2018.
- 08 Mar 2018 New trial record
- 01 Mar 2018 Pre-specified primary analysis from this trial presented in a Biohaven Pharmaceutical Holding Company Media Release.